Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.
作者信息
Santos Silvia Regina Cavani Jorge, Campos Edvaldo Vieira, Sanches Cristina, Gomez David Souza, Ferreira Marcus Castro
机构信息
School of Pharmaceutical Sciences, Universidade de São Paulo - São Paulo/SP, Brazil.
出版信息
Clinics (Sao Paulo). 2010 Feb;65(2):237-43. doi: 10.1590/S1807-59322010000200017.
Abstract
摘要
相似文献
1
Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.
Clinics (Sao Paulo). 2010 Feb;65(2):237-43. doi: 10.1590/S1807-59322010000200017.
2
3
Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party.
Lancet. 1991 Jun 29;337(8757):1577-80.
4
Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
Ther Drug Monit. 2017 Oct;39(5):505-513. doi: 10.1097/FTD.0000000000000438.
5
Variability of plasma fluconazole levels in patients with hematologic malignancy.
Clin Infect Dis. 1997 Jan;24(1):86-7. doi: 10.1093/clinids/24.1.86.
6
DETERMINATION OF FLUCONAZOLE IN HUMAN PLASMA BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY.
Acta Pol Pharm. 2015 Mar-Apr;72(2):227-33.
7
Serum level determination of fluconazole by high-performance liquid chromatography and bioassay.
Zentralbl Bakteriol. 1996 Apr;283(4):492-6. doi: 10.1016/s0934-8840(96)80126-5.
8
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.
Antimicrob Agents Chemother. 2013 Oct;57(10):4999-5004. doi: 10.1128/AAC.00707-13. Epub 2013 Jul 29.
9
Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring.
J Pharm Biomed Anal. 2020 Jan 30;178:112952. doi: 10.1016/j.jpba.2019.112952. Epub 2019 Oct 25.
10
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
Antimicrob Agents Chemother. 2009 May;53(5):2223-4. doi: 10.1128/AAC.00240-09. Epub 2009 Mar 2.
引用本文的文献
1
Determination of Fluconazole in Children in Small Blood Volumes Using Volumetric Absorptive Microsampling (VAMS) and Isocratic High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV) Detection.
Pharmaceutics. 2025 May 1;17(5):592. doi: 10.3390/pharmaceutics17050592.
2
Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK/PD) approach.
Clinics (Sao Paulo). 2024 Sep 23;79:100491. doi: 10.1016/j.clinsp.2024.100491. eCollection 2024.
3
Evaluating the Effect of Azole Antifungal Agents on the Stress Response and Nanomechanical Surface Properties of Aspcl2.2.
Molecules. 2020 Jul 23;25(15):3348. doi: 10.3390/molecules25153348.
4
Widespread Lichtheimia Infection in a Patient with Extensive Burns: Opportunities for Novel Antifungal Agents.
Mycopathologia. 2019 Feb;184(1):121-128. doi: 10.1007/s11046-018-0281-6. Epub 2018 Jul 2.
5
Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis.
Biomed Res Int. 2015;2015:396894. doi: 10.1155/2015/396894. Epub 2015 Jan 12.
6
Penetration of micafungin into the burn eschar in patients with severe burns.
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):93-7. doi: 10.1007/s13318-013-0146-9. Epub 2013 Jun 15.
7
Mechanical evaluation of the resistance and elastance of post-burn scars after topical treatment with tretinoin.
Clinics (Sao Paulo). 2011;66(11):1949-54. doi: 10.1590/s1807-59322011001100016.
8
Micafungin concentrations in the plasma and burn eschar of severely burned patients.
Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5. doi: 10.1128/AAC.05381-11. Epub 2011 Nov 14.
本文引用的文献
1
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Clin Pharmacokinet. 2008;47(10):635-54. doi: 10.2165/00003088-200847100-00002.
2
Validated HPLC method for the determination of fluconazole in human plasma.
Biomed Chromatogr. 2006 Jan;20(1):1-3. doi: 10.1002/bmc.538.
3
Program to restrict use of i.v. fluconazole.
Am J Health Syst Pharm. 2004 Aug 15;61(16):1695-8. doi: 10.1093/ajhp/61.16.1695.
4
A new, rapid, fully automated method for determination of fluconazole in serum by column-switching liquid chromatography.
Ther Drug Monit. 2004 Aug;26(4):425-31. doi: 10.1097/00007691-200408000-00013.
5
Dosing guidelines for fluconazole in patients with renal failure.
Nephrol Dial Transplant. 2003 Nov;18(11):2227-31. doi: 10.1093/ndt/gfg363.
6
Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.
Antimicrob Agents Chemother. 2000 Oct;44(10):2715-8. doi: 10.1128/AAC.44.10.2715-2718.2000.
7
[Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].
Rev Cubana Med Trop. 1999 Jan-Apr;51(1):55-7.
8
Fluconazole use in burns patients.
Burns. 2000 Feb;26(1):109-10. doi: 10.1016/s0305-4179(99)00101-1.
9
Pharmacokinetics of antibiotics in burn patients.
J Antimicrob Chemother. 1999 Sep;44(3):319-27. doi: 10.1093/jac/44.3.319.
10
Fluconazole pharmacokinetics in burn patients.
Antimicrob Agents Chemother. 1998 Apr;42(4):930-3. doi: 10.1128/AAC.42.4.930.
Zotero 插件